AlDoughaim Maha, AlSuhebany Nada, AlZahrani Mohammed, AlQahtani Tariq, AlGhamdi Sahar, Badreldin Hisham, Al Alshaykh Hana
College of Pharmacy, King Saud Bin Abdul Aziz University for Health Sciences (KSAU-HS), King Abdullah International Medical Research Center (KAIMRC), Riyadh, Saudi Arabia.
Pharmaceutical Care Devision, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
Clin Med Insights Oncol. 2024 Nov 17;18:11795549241298541. doi: 10.1177/11795549241298541. eCollection 2024.
The discovery of cancer-specific biomarkers has resulted in major advancements in the field of cancer diagnostics and therapeutics, therefore significantly lowering cancer-related morbidity and mortality. Cancer biomarkers can be generally classified as prognostic biomarkers that predict specific disease outcomes and predictive biomarkers that predict disease response to targeted therapeutic interventions. As research in the area of predictive biomarkers continues to grow, precision medicine becomes far more integrated in cancer treatment. This article presents a general overview on the most recent advancements in the area of cancer biomarkers, immunotherapy, artificial intelligence, and pharmacogenomics of the Middle East.
癌症特异性生物标志物的发现推动了癌症诊断和治疗领域的重大进展,从而显著降低了癌症相关的发病率和死亡率。癌症生物标志物通常可分为预测特定疾病结局的预后生物标志物和预测疾病对靶向治疗干预反应的预测生物标志物。随着预测性生物标志物领域的研究不断发展,精准医学在癌症治疗中的整合程度越来越高。本文概述了中东地区在癌症生物标志物、免疫疗法、人工智能和药物基因组学领域的最新进展。